Osimertinib-Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy.

Osimertinib–savolitinib significantly improved progression-free survival versus platinum–pemetrexed in EGFR-mutated advanced NSCLC after progression on osimertinib, with hazard ratio 0.55.

• Why it matters: After progression during EGFR-TKI therapy, effective options are needed for EGFR-mutated advanced NSCLC with MET overexpression and/or MET amplification.
• What they did: In an international phase 3 open-label trial, 338 patients were randomized 1:1 to osimertinib 80 mg daily plus savolitinib 300 mg twice daily versus intravenous platinum–pemetrexed, with progression-free survival assessed by blinded independent central review.
• The result: Osimertinib–savolitinib also significantly prolonged overall survival (hazard ratio 0.68) and showed 12-month progression-free survival of 36% versus 10%, with peripheral edema (49%) as the most frequent adverse event.